Calleja, José LuisDelgado, SalvadoraVal, Adolfo delHervás, AntonioLarraona, José LuisTerán, ÁlvaroColon Cancer Study GroupArgüelles Arias, Federico2025-05-162025-05-162016-03Calleja, J.L., Delgado, S., Val, A.d., Hervás, A., Larraona, J.L., Terán, Á.,...,Argüelles Arias, F. (2016). Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia. International Journal of colorectal disease, 31, 543-551. https://doi.org/10.1007/s00384-015-2461-x.0179-19581432-1262https://hdl.handle.net/11441/172861Purpose The purpose of the study was to evaluate the efficacy of preoperative intravenous (IV) ferric carboxymaltose (FCM) administration vs. no-IV iron in colon cancer (CC) anemic patients undergoing elective surgery with curative intention. Methods This was a multicenter, observational study includ- ing two cohorts of consecutive CC anemic patients: the no-IV iron treatment group was obtained retrospectively while FCM-treated patients were recorded prospectively. Results A total of 266 patients were included: 111 received FCM (median dose 1000 mg) and 155 were no-IV iron sub- jects. Both groups were similar in terms of demographic char- acteristics, tumor location, surgical approach, and intra- operative bleeding severity. The FCM group showed a signif- icant lower need for red blood cell (RBC) transfusion during the study (9.9 vs. 38.7 %; OR: 5.9, p<0.001). In spite of lower hemoglobin levels at baseline diagnosis and lower transfusion rates in the FCM group, the proportion of responders was significantly higher with respect to the no-IV group both at hospital admission (48.1 vs. 20.0 %, p<0.0001) and at 30 days post-surgery (80.0 vs. 48.9 %, p<0.0001). The percentage of patients with normalized hemoglobin levels was also higher in the FCM group (40.0 vs. 26.7 % at 30 days, p<0.05). A lower number of reinterventions and post-surgery complications were seen in the FCM group (20.7 vs. 26.5 %; p=0.311). The FCM group presented a significant shorter hospital stay (8.4±6.8 vs. 10.9±12.4 days to discharge; p<0.001). Conclusions Preoperative ferric carboxymaltose treatment in patients with CC and iron deficiency anemia significantly re- duced RBC transfusion requirements and hospital length of stay, reaching higher response rates and percentages of nor- malized hemoglobin levels both at hospital admission and 30 days post-surgery.application/pdf9 p.engAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/Iron deficiency anemiaColon cancer surgeryIron intravenous administrationFerric carboxymaltoinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccesshttps://doi.org/10.1007/s00384-015-2461-x